Show simple item record

dc.contributor.authorRasco, D
dc.contributor.authorMiddleton, M
dc.contributor.authorGonzalez, Rene
dc.contributor.authorCorrie, P
dc.contributor.authorPavlick, A
dc.contributor.authorLorigan, Paul C
dc.contributor.authorPlummer, R
dc.contributor.authorGore, M
dc.contributor.authorHerbert, C
dc.contributor.authorAgarwala, S
dc.contributor.authorLogan, T
dc.contributor.authorKhleif, S
dc.contributor.authorPapadopoulos, K
dc.contributor.authorRangachari, L
dc.contributor.authorSuri, A
dc.contributor.authorXu, Q
dc.contributor.authorKneissl, M
dc.contributor.authorBozon, V
dc.contributor.authorOlszanski, A
dc.date.accessioned2016-01-06T10:08:13Zen
dc.date.available2016-01-06T10:08:13Zen
dc.date.issued2015en
dc.identifier.citationPhase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. 2015, 51 S53-S54 Eur J Canceren
dc.identifier.urihttp://hdl.handle.net/10541/592919en
dc.language.isoenen
dc.titlePhase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanomaen
dc.title.alternativePhase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentSouth Texas Accelerated Research Therapeutics START, Oncology,San Antonio, USAen
dc.identifier.journalEuropean Journal of Canceren


This item appears in the following Collection(s)

Show simple item record